SCHEMBL23326564

SCHEMBL23326564

COc1nc(C)nc2[nH]c(=O)ccc12

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 6/20 0.38
PDE3B Q13370 3/20 0.37
PDE3A Q14432 3/20 0.37
MAT2A P31153 1/20 0.35
PIM1 P11309 2/20 0.35
DYRK2 Q92630 2/20 0.35
DYRK1B Q9Y463 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ADORA1 P30542 3/20 0.35
ADORA2A P29274 2/20 0.35
BTK Q06187 1/20 0.35
KMT2A Q03164 2/20 0.34
CDK9 P50750 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
CREBBP Q92793 1/20 0.34
STAT3 P40763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30696421 0.82 MAT2A (0.35) PDE3BPDE3AMAT2AKDM4EADORA1
SCHEMBL8805431 0.79 PDE3B (0.44) PDE3BPDE3AKDM4EADORA1ADORA2A
SCHEMBL25112473 0.78 CNR2 (0.36) PDE3BPDE3AKMT2A
SCHEMBL31253486 0.76 PDE3B (0.39) PDE3BPDE3AKDM4EADORA1ADORA2A
SCHEMBL30556397 0.76 ENPP1 (0.42) PDE3BPDE3AKMT2A
SCHEMBL24671871 0.76 ENPP1 (0.42) PDE3BPDE3AKMT2A
SCHEMBL29918677 0.73 PDE3B (0.40) PDE3BPDE3AKDM4EADORA1ADORA2A
SCHEMBL29755433 0.73 KDM4E (0.37) PDE3BPDE3AKDM4EADORA1ADORA2A
SCHEMBL23326631 0.73 PDE3B (0.36) DYRK1APDE3BPDE3APIM1DYRK2
SCHEMBL29799768 0.73 PDE3B (0.36) DYRK1APDE3BPDE3APIM1DYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620531-A2 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2025-09-24 EP disclosed
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2025-03-25 US disclosed
US-20240109891-A1 NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 US disclosed
CN-117561258-A Novel substituted tricyclic aza heterocycles as SOS1 inhibitors 唯久生物技术(苏州)有限公司 2024-02-13 CN disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
EP-4055017-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-09-14 EP disclosed
WO-2022187236-A1 NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-09-09 WO disclosed
CN-114901662-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2022-08-12 CN disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109891-A1 NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 DYRK1A 1276/4885PDE3B 4268/4885PDE3A 4043/4885
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 DYRK1A 1861/4885PDE3B 2354/4885PDE3A 2110/4885
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 DYRK1A 2337/4885PDE3B 2782/4885PDE3A 2685/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 DYRK1A 2337/4885PDE3B 2782/4885PDE3A 2685/4885
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof SOST, SOS1, SOS2 DYRK1A 2337/4885PDE3B 2782/4885PDE3A 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.